Copy For Citation
DURAK A., OLĞAR Y., Degirmenci S., AKKUŞ E., TUNCAY E., Turan B.
CARDIOVASCULAR DIABETOLOGY, vol.17, 2018 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
17
-
Publication Date:
2018
-
Doi Number:
10.1186/s12933-018-0790-0
-
Journal Name:
CARDIOVASCULAR DIABETOLOGY
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Keywords:
Diabetes, SGLT2 inhibitors, Heart function, Electrophysiology, Oxidative stress, Insulin resistance, OXIDATIVE STRESS, NA+/H+ EXCHANGER, DYSFUNCTION, HEART, EMPAGLIFLOZIN, OBESITY, CARDIOMYOCYTES, MORTALITY, ZN2+, PATHOPHYSIOLOGY
-
Eskisehir Osmangazi University Affiliated:
No
Abstract
Background: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect.